Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many advanced stage malignancies. Immune checkpoints are one of the immune systems protective mechanisms, that prevents over activation which can result in tissue damage and the development of various autoimmune diseases. Tumour cells can use these checkpoints to their advantage to evade the bodies own endogenous anti-tumour response. Blocking these checkpoints with monoclonal antibodies can result in a very robust anti-tumour response but also many off-target effects which are known as immune-related adverse effects (irAE)
Here you will find information on the most common rheumatic immune-related adverse events (Rh-irAE) with current and reliable information developed by CanRIO topic experts.